Anti-Pseudomonas aeruginosa Compound, 1,2,3,4-Tetrahydro-1,3,5-triazine Derivative, Exerts Its Action by Primarily Targeting MreB

スポンサーリンク

概要

• 論文の詳細を見る

• In order to find new anti-Pseudomonas agents, we carried out whole-cell based P. aeruginosa growth assay, and identified 1,2,3,4-tetrahydro-1,3,5-triazine (Compound A). This compound showed anti-Pseudomonas activity against wild as well as pumpless strain equally at a same concentration. Also, this compound was structurally very similar to A22, which is known to inhibit the bacterial actin-like protein MreB. By the analysis of resistant strains, the primary target of this compound in P. aeruginosa was definitely confirmed to be MreB. In addition, these compounds showed a bacteriostatic effect, and induced the morphology changes in P. aeruginosa from rod shape to sphere shape, which leads to be clinically favorable in terms of susceptibility to phagocytosis and release of endotoxin. These results display that Compound A is a very attractive compound which shows anti-P. aeruginosa activity based on inhibition of MreB without being affected by efflux pumps, and could provide a new step toward development of new promising anti-Pseudomonas agents, MreB inhibitors.

著者

• Yamashita Makoto

  Biological Research Laboratories Daiichi Sankyo Co. Ltd.

• Muramatsu Yasunori

  Lead Discovery & Optimization Research Laboratories II, Daiichi Sankyo Co., Ltd.

• Tsuji Hayato

  Lead Discovery & Optimization Research Laboratories II, Daiichi Sankyo Co., Ltd.

• Yamachika Shinichiro

  Oncology Research Laboratories, Daiichi Sankyo Co., Ltd.

• Sugihara Chika

  Lead Discovery & Optimization Research Laboratories II, Daiichi Sankyo Co., Ltd.

• Kamai Yasuki

  Oncology Research Laboratories, Daiichi Sankyo Co., Ltd.

関連論文

• RS-1748, a Novel CC Chemokine Receptor 4 Antagonist, Inhibits Ovalbumin-Induced Airway Inflammation in Guinea Pigs
• Synthesis and Anti-influenza Evaluation of Polyvalent Sialidase Inhibitors Bearing 4-Guanidino-Neu5Ac2en Derivatives
• Studies on Novel Bacterial Translocase I Inhibitors, A-500359s I. Taxonomy, Fermentation, Isolation, Physico-chemical Properties and Structure Elucidation of A-500359 A,C,D and G
• Studies on Novel Bacteria Translocase I Inhibitors, A-500359s : V. Enhanced Production of Capuramycin and A-500359 A in Streptomyces griseus SANK 60196
• Studies on Novel Bacterial Translocase I Inhibitors, A-500359s III. Deaminocaprolactam Derivatives of Capuramycin: A-500359 E, F, H, M-1 and M-2
• A-503083 A, B, E and F, Novel Inhibitors of Bacterial Translocase I, Produced by Streptomyces sp. SANK 62799
• Studies on Novel Bacterial Translocase I Inhibitors, A-500359s II. Biological Activities of A-500359 A, C, D and G
• High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals
• Anti-Pseudomonas aeruginosa Compound, 1,2,3,4-Tetrahydro-1,3,5-triazine Derivative, Exerts Its Action by Primarily Targeting MreB

スポンサーリンク